about
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the fi...
Read More
2.60
-0.06
(-2.26%)
151.0K
XNAS Volume
XNAS 08 Aug, 2025 5:30 PM (EDT)
Low Financial Strength
Expensive Valuation
Technically Moderately Bullish
Momentum Trap
These stocks are with a bad quality and poor financial score ranging from medium to expensive valuation. Rising technical aspects may attract investors, but, weak financials cannot be overlooked.
View Similar
Embed DVM
Cellectis - ADR Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..